Kiniksa Pharmaceuticals International, plc
Company Stats
- Market Cap
- $5.8B
- as of Sep 30, 2026
- Shares Outstanding
- 78.0M
- Free Float
- 42.0%
Income Statement
- Revenue
- $677.6M
- Operating Income
- $77.2M
- Net Income
- $59.0M
- EBITDA
- $77.4M
- Revenue Growth, 3Y
- 45.5%
- FCF Margin, 3Y Avg
- 10.3%
- FCF Margin, Worst Year
- 4.9%
Cash Flow
- Free Cash Flow
- $136.4M
- FCF Yield
- 2.3%
- Owner FCF Yield
- 1.7%
Balance Sheet
- Cash & Equivalents
- $165.6M
Returns & Capital
- SBC, 3Y Avg
- $31.6M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $677.6M | $136.4M | 20.1% |
| FY2024 | $423.2M | $25.4M | 6.0% |
| FY2023 | $270.3M | $13.2M | 4.9% |
| FY2022 | $220.2M | $5.7M | 2.6% |
| FY2021 | $38.5M | -$126.7M | -328.7% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 13, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back